Imunoexpression of Ki-67 and p53 in Rectal Cancer Tissue After Treatment with Neoadjuvant Chemoradiation

Andrade, Nara Rosana; Oshima, Celina Tizuko Fujiyama; Gomes, Thiago Simão; Neto, Ricardo Artigiani; Forones, Nora Manoukian

doi:10.1007/s12029-010-9225-1

Cited by 5 publications

(3 citation statements)

References 28 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All candidate variables for histologic marker analysis were p53, Ki67, TS, BAX, HIF1α, ALDH1, CD166, p21, EpCAM, CD44, CD133, which were selected due to potential candidates for cancer stem cell markers or histologic prognostic factors according to recent research on rectal cancer, with consideration of and technical availability [7,11-17]. …”

Section: Methodsmentioning

confidence: 99%

p21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer

et al. 2014

View full text Add to dashboard Cite

BackgroundPre-operative chemoradiotherapy (CRT) is the standard treatment in clinical stage T3/4 or node positive rectal cancer. However, there are no established biomarkers that can predict the pathological response and clinical outcome to CRT.MethodsImmunohistochemical staining was performed in tissue arrays constructed from core tissue specimens taken before treatment and from operative specimens from 112 patients who received 5-FU based pre-operative CRT and surgery. Expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1α and ALDH1 were assessed and correlated with tumor regression grades and disease free survival.ResultsOf the 112 patients (M/F 74/38, median age: 62), 20 (17.9%) patients achieved pathologic complete remission (pCR). In analyzing the associations between marker expressions and tumor regression grades, high p21 expression at the pretreatment biopsy was significantly associated with non-pCR (p = 0.022) and poor disease free survival (median DFS - low vs high p21: 75.8 vs 58.1 months, p = 0.002). In the multivariate analysis, high p21 expression level at the pre-treatment biopsy was significantly associated with poor DFS (p = 0.001, HR 6.14; 95% CI 2.03, 18.55). High CD166 expression level at the pretreatment biopsy was also associated with poor DFS (p = 0.003; HR 5.61; 95% CI 1.81, 17.35).ConclusionThese show high p21 and CD166 expression at the pretreatment biopsy were associated with tumor regression and poor prognosis in patients treated with 5-FU based CRT. Larger, prospective and functional studies are warranted to determine the role of p21 and CD166 as predictive biomarker of response to CRT.

show abstract

Section: Methodsmentioning

confidence: 99%

p21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Ki-67 широко применяется для оценки эффективности лечения злокачественных опухолей у взрослого населения [9][10][11]. В 2003 г. был описан способ прогноза при остеосаркомах у детей с помощью исследования уровня моноклональных антител Ki-67 [12].…”

unclassified

Ki-67 as a Marker of Response to Treatment for Embryonal Tumors

Popovyan¹,

Frantsiyants²,

Kuznetsov³

et al. 2021

СПНО (MPSE)

View full text Add to dashboard Cite

“…Так, экспрессия мутантного типа гена р53 в злокаче-ственных клетках повышает устойчивость к по-вреждению ДНК под воздействием радиации и химиотерапии, что обусловлено его накоплением [19]. В другом исследовании корреляции между экспрессией р53 и опухолевым ответом после НАХЛТ установить не удалось [20].…”

unclassified

Molecular Genetic Markers as Predictors of Tumor Response to Neoadjuvant Chemotherapy for Rectal Cancer

et al. 2016

View full text Add to dashboard Cite

Imunoexpression of Ki-67 and p53 in Rectal Cancer Tissue After Treatment with Neoadjuvant Chemoradiation

Cited by 5 publications

References 28 publications

p21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer

p21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer

Ki-67 as a Marker of Response to Treatment for Embryonal Tumors

Molecular Genetic Markers as Predictors of Tumor Response to Neoadjuvant Chemotherapy for Rectal Cancer

Contact Info

Product

Resources

About